Clinical Trial Update: PD-1 Inhibitor Plus G-CSF in Recurrent/Metastatic NPC With First-line Treatment Failure [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating a PD-1 inhibitor with G-CSF as first-line treatment failure in recurrent/metastatic nasopharyngeal carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• G-CSF (granulocyte colony-stimulating factor)
• PD-1 inhibitor

Snippet

Sponsor: Sun Yat-sen University | Conditions: PD-1 Inhibitor, G-CSF | Phase 2 | Status: UNKNOWN